FLGT — Stock Film
STOCK FILMSCENE 1/11FLGT · $20.16
Stock Expert AI presents
FLGT
Fulgent Genetics, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Fulgent Genetics, Inc. A quick introduction.

On the stock market since 2016, it operates in the world of health and science. It has 1,313 employees. Now — the numbers.

on the stock market since 2016
1,313 employees
$572.6M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.2.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
Sales have been shrinking.

An average decline of 24% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$992.6M
2021
$619M
2022
$289.2M
2023
$283.5M
2024
$322.7M
2025
In the vault right now:
$0
DEBT: $7.7M
At this pace, that money lasts about 5.6 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
46
weak

Clearly below the class average.

FINANCIAL STRENGTH
49
weak

Clearly below the class average.

VALUATION
65
strong

Clearly above the class average — a step short of the very top.

GROWTH
13
very weak

Clearly below the class average.

PRICE MOMENTUM
51
average

The price is looking for direction — no strong breakout, no collapse.

WORTH WATCHING

Growth: Sales growth trails the sector average.

Business Quality: Profit power and business quality trail similar companies in the sector.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking8/10
WEAK SPOTS
The stock has lost its spark0/10
THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 82% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
The product is selling

Sales run at $322.7M a year. A small number, but proof the product has real buyers.

2
THE BRIGHT SIDE · 2/3
Strong cash, light debt

There is $336.1M in the vault; even if every debt were paid off, $328.4M would remain.

3
THE BRIGHT SIDE · 3/3
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

1
THE RISKS · 1/3
Running at a loss

A loss of $60.5M against $322.7M in annual sales.

2
THE RISKS · 2/3
Executives lean toward selling

Over the last 12 months, executives reported 69 sells against just 20 buys. Not an alarm bell by itself, but a number worth watching.

3
THE RISKS · 3/3
The price sits above analysts’ target

The stock trades 26% above the average analyst price target.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, FLGT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: FLGT is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film